Compare · FENC vs MRNA
FENC vs MRNA
Side-by-side comparison of Fennec Pharmaceuticals Inc. (FENC) and Moderna Inc. (MRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FENC and MRNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $61.59B, about 146.1x FENC ($421.5M).
- Over the past year, FENC is up 34.3% and MRNA is up 537.5% - MRNA leads by 503.1 points.
- MRNA has been more active in the news (15 items in the past 4 weeks vs 9 for FENC).
- MRNA has more recent analyst coverage (25 ratings vs 5 for FENC).
- Company
- Fennec Pharmaceuticals Inc.
- Moderna Inc.
- Price
- $12.04-2.55%
- $154.14+9.79%
- Market cap
- $421.5M
- $61.59B
- 1M return
- +25.89%
- +179.70%
- 1Y return
- +34.32%
- +537.47%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 9
- 15
- Recent ratings
- 5
- 25
Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product PEDMARK, a formulation of Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest FENC
- Former Director Raykov Rosty was granted 2,778 shares and sold $121,100 worth of shares (10,000 units at $12.11) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 124,411 units (SEC Form 4)
- Chief Medical Officer Sayad Pierre Sargis was granted 168 shares and sold $146,160 worth of shares (12,000 units at $12.18), decreasing direct ownership by 55% to 9,519 units (SEC Form 4)
- Chief Commercial Officer Evans Terry L was granted 168 shares, increasing direct ownership by 0.79% to 21,519 units (SEC Form 4)
- Chief Strategy Officer Cioffi Christiana Marie was granted 156 shares, increasing direct ownership by 0.64% to 24,644 units (SEC Form 4)
- Chief Executive Officer Hackman Jeffrey S. was granted 1,159 shares, increasing direct ownership by 2% to 66,302 units (SEC Form 4)
- CHIEF FINANCIAL OFFICER Andrade Robert was granted 1,703 shares, increasing direct ownership by 0.71% to 241,306 units (SEC Form 4)
- CHIEF FINANCIAL OFFICER Andrade Robert sold $883,500 worth of shares (75,000 units at $11.78) as part of a pre-agreed trading plan and exercised 21,928 shares at a strike of $5.10, decreasing direct ownership by 18% to 239,603 units (SEC Form 4) (tax withholding)
- SEC Form 10-Q filed by Fennec Pharmaceuticals Inc.
- Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
- Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026
Latest MRNA
- Moderna Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
- Moderna to Present at Upcoming Conferences in September 2026
- President Hoge Stephen converted options into 2,048 shares and covered exercise/tax liability with 991 shares, increasing direct ownership by 0.07% to 1,484,905 units (SEC Form 4) to satisfy tax liability
- Chief Legal Officer Klinger Shannon Thyme converted options into 1,103 shares and covered exercise/tax liability with 535 shares, increasing direct ownership by 0.77% to 74,129 units (SEC Form 4) to cover withholding tax
- Chief Financial Officer Mock James M converted options into 1,103 shares and covered exercise/tax liability with 535 shares, increasing direct ownership by 0.85% to 67,004 units (SEC Form 4) to satisfy withholding obligation
- Moderna upgraded by Argus with a new price target
- Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes
- Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines
- Moderna Announces Proposed Private Placement of $2.0 Billion of Convertible Senior Notes
- A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity